Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating

Bank of America Securities analyst Jason Gerberry has maintained their bullish stance on BHVN stock, giving a Buy rating on May 14.

Jason Gerberry has given his Buy rating due to a combination of factors that highlight Biohaven Ltd.’s promising prospects. The recent R&D day provided clarity on the company’s pipeline, particularly the troriluzole for spinocerebellar ataxia (SCA), which is on track for a significant regulatory milestone in the fourth quarter of 2025. The data presented reinforced the robustness of the real-world evidence and suggested favorable safety profiles, which are crucial for the upcoming advisory committee discussions.
Additionally, new data on the Kv7 program indicated good tolerability and central nervous system activity, addressing previous investor concerns and potentially differentiating Biohaven from its competitors. The company’s novel degrader data also supports a flexible dosing value proposition, further validating their broader platform. These developments, coupled with the company’s current undervaluation, present re-rating opportunities that justify the Buy rating.

BHVN’s price has also changed dramatically for the past six months – from $46.380 to $15.060, which is a -67.53% drop .